Emirates Oncology Society hosted a panel discussion to outline guidelines for diagnosis and treatment of prostate cancer

Dubai, UAE: Around 4,500 cases of cancer are reported in a year in the UAE and the country aims to bring down cancer fatalities to nearly 18 per cent by 2021. Reducing the number of deaths due to prostate cancer is one of the key performance indicators of the pillar of world-class health care of the UAE National Agenda. This was a key topic at a recently held panel discussion that focused on management of prostate cancer patients held by Emirates Urological Society.

The panel discussion witnessed the presence of several key experts. Moderating the panel discussion was Dr Humaid Al Shamsi, President of Emirates Oncology Society (EOS). He was joined by other experts including Dr Neal Shone, Dr Jawaher Ali Ansari and Dr Yasser Farhat.

“Early detection is key to managing prostate cancer. When the disease is in its initial stages (0-II), less aggressive treatment is needed, and the

Read More

ViewRay to Host Physician-led Webinar for Investors and Analysts at the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting

CLEVELAND, Oct. 1, 2020 /PRNewswire/ — ViewRay, Inc. (Nasdaq: VRAY) today announced that the Company will host a virtual physician-led informational discussion for investors and analysts during the 2020 American Society of Radiation Oncology (ASTRO) Annual Meeting.


Physician-led Webinar for Investors and Analysts at 2020 ASTRO Annual Meeting


Tuesday, October 27, 2020


9:00 a.m. – 10:00 a.m. MTN


Registration is required to attend and will close an hour prior to the start. Please register at https://www.bigmarker.com/viewray/Physician-led-Webinar-for-Investors-and-Analysts-at-2020-ASTRO-Annual-Meeting?utm_bmcr_source=Press. An archived replay of the meeting will be available within 24 hours on ViewRay’s investor relations website at http://investors.viewray.com/events-and-presentations/upcoming-events.

Guest Speakers:     

Dr. John Bayouth is a tenured professor and the Bhudatt Paliwal endowed chair of the Radiation Oncology Physics Division in the Department of Human Oncology at the University of Wisconsin in Madison, one of the nation’s premier radiation oncology physics programs. He is also the director of

Read More

Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020

ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following the closing of the Congress’ sessions on Saturday, September 19, 2020, beginning at 22:00 (10:00 p.m.) CEST / 4:00 p.m. EDT / 1:00 p.m. PDT.

During the briefing, Exelixis management and invited guests from the clinical community will discuss and provide context for the cabozantinib clinical data presented at the Congress. Exelixis previously announced that detailed results from CheckMate -9ER, the phase 3 pivotal trial evaluating CABOMETYX® (cabozantinib) in combination with Opdivo® (nivolumab) compared with sunitinib in previously untreated patients with advanced or metastatic renal cell carcinoma, will be presented during the Congress’ Presidential Symposium I earlier in the day. The investor briefing will also review data from COSMIC-021, the

Read More